Efgartigimod is a neonatal Fc receptor (FcRn) blocker designed to reduce pathogenic IgG autoantibody levels that have shown efficacy in MG and some GAD ab diseases such as stiff-person syndrome, also producing a decrease in serum GAD ab [25,26]. The gene discussed is GAD1; the disease is myasthenia gravis.